Full Press Release Details
Galapagos reports half-year 2024 financial results and provides second quarter
Webcast presentation with management on 2 August 2024, at 14:00 CET / 8:00 AM ET, www.glpg.com
Mechelen, Belgium; August 1, 2024, 22:01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) today announced its
half-year 2024 financial results and provided a second quarter and post-period update and the outlook for the remainder of 2024. The results are further detailed in the H1 2024 financial report available on the financial reports section of the
We are very pleased with the progress we have made in delivering on our Forward, Faster strategy, said
Dr. Paul Stoffels1, Galapagos CEO and Chairman of the Board of Directors. We are on track with key regulatory milestones, having submitted the IND for our Phase 1/2 study of
GLPG5101 in the U.S., and the CTA for the Phase 2 study of GLPG5201 in Europe, with plans for an upcoming IND filing in the U.S. for GLPG5201. With these submissions, Galapagos is pioneering innovative approaches in cell therapy with the potential
to administer fresh, fit CAR-T cells within a vein-to-vein time of just seven days - critical for patients with rapidly advancing
cancers. Our innovation strategy, powered by our unique technology platforms and value-enriching collaborations has significantly expanded our pipeline. With over 15 ongoing preclinical programs in oncology and immunology, our ambition to initiate
at least one first-in-human study in 2025 and introduce at least two new clinical candidates annually starting in 2026, positions us strongly for sustained value creation.
Thad Huston, Galapagos CFO and COO, added: Strengthened by our newest collaboration with Blood
Centers of America to expand our cell therapy manufacturing network across the U.S, we are gearing up for our pivotal CAR-T studies and commercial readiness. We continue to evaluate business development
opportunities and were happy to announce a clinical collaboration with an option to exclusively license Adaptimmune s next-generation TCR T-cell therapy, uza-cel.
This aligns well with our strategy to advance novel cell therapies and enables us to expand our portfolio to include treatments for solid tumors. We reaffirm our 2024 outlook, with key pipeline catalysts on track and cash burn guidance, excluding
business development, in the range of 280-320 million.
HALF-YEAR 2024 AND POST-PERIOD
Regulatory, clinical, and manufacturing progress with CD19 CAR-T candidates, GLPG5101 in
relapsed/refractory non-Hodgkin lymphoma (R/R NHL) and GLPG5201 in chronic lymphocytic leukemia (R/R CLL) & Richter transformation (RT), and submitted protocol amendment for BCMA CAR-T candidate, GLPG5301, in relapsed/refractory multiple myeloma (R/R MM).
execute on innovation strategy with license agreements and research collaborations in small molecules and cell therapies in solid tumor indications.
Progressed proprietary R&D pipeline of >20 clinical and preclinical small molecule and cell therapy programs in oncology and immunology.
At the Annual and Extraordinary Shareholders Meetings held on
30 April 2024, all proposed resolutions were approved.
FINANCIAL PERFORMANCE
half-year 2024 key figures (consolidated)
( millions, except basic & diluted earnings per share)
| Six months ended 30 June | % Change | |||||||||||
| 2024 | 2023 | |||||||||||
| Supply revenues | 19.1 | |||||||||||
| Collaboration revenues | 121.2 | 118.6 | +2 | % | ||||||||
| Total net revenues | 140.3 | 118.6 | +18 | % | ||||||||
| Cost of sales | (19.1 | ) | ||||||||||
| R&D expenses | (145.2 | ) | (108.7 | ) | +34 | % | ||||||
| G&A ii and S&M iii expenses | (63.9 | ) | (57.9 | ) | +10 | % | ||||||
| Other operating income | 16.6 | 20.3 | -18 | % | ||||||||
| Operating loss | (71.3 | ) | (27.7 | ) | ||||||||
| Fair value adjustments and net exchange differences | 49.5 | 0.2 | ||||||||||
| Net other financial result | 48.9 | 32.9 | ||||||||||
| Income taxes | 1.1 | (12.7 | ) | |||||||||
| Net profit/loss (-) from continuing operations | 28.2 | (7.3 | ) | |||||||||
| Net profit from discontinued operations, net of tax | 71.0 | 35.6 | ||||||||||
| Net profit of the period | 99.2 | 28.3 | ||||||||||
| Basic and diluted earnings per share ( ) | 1.51 | 0.43 | ||||||||||
| Current financial investments, cash & cash equivalents | 3,430.4 | 3,901.5 | (*) |
DETAILS OF THE FINANCIAL RESULTS OF THE FIRST HALF YEAR OF 2024
As a consequence of the transfer of our Jyseleca business to Alfasigma, the results related to
Jyseleca for the first half-year of 2024 are presented separately from the results of our continuing operations in the line Net profit from discontinued operations, net of tax in
our consolidated income statement. The comparative first half-year of 2023 has been restated accordingly for the presentation of the results related to the Jyseleca business.
Results from our continuing operations
operating loss from continuing operations for the six months ended 30 June 2024 was 71.3 million, compared to an operating loss of 27.7 million for the six months ended 30 June 2023.
financial income in the first six months of 2024 amounted to 98.4 million, compared to net financial income of 33.1 million for the first six months of 2023.
Net profit from continuing operations for the first six months of 2024 was 28.2 million, compared to a net
loss from continuing operations of 7.3 million for the first six months of 2023.
Results from discontinued operations
| Six months ended 30 June | % Change | |||||||||||
| 2024 | 2023 | |||||||||||
| Product net sales | 11.3 | 54.3 | -79 | % | ||||||||
| Collaboration revenues | 26.0 | 155.9 | -83 | % | ||||||||
| Total net revenues | 37.3 | 210.2 | -82 | % | ||||||||
| Cost of sales | (2.0 | ) | (7.8 | ) | -74 | % | ||||||
| R&D expenses | (11.3 | ) | (103.1 | ) | -89 | % | ||||||
| G&A and S&M expenses | (10.3 | ) | (63.7 | ) | -84 | % | ||||||
| Other operating income | 54.6 | 3.4 | ||||||||||
| Operating profit | 68.3 | 39.0 | +75 | % | ||||||||
| Net financial result | 2.8 | (2.5 | ) | |||||||||
| Income taxes | (0.1 | ) | (0.9 | ) | ||||||||
| Net profit from discontinued operations | 71.0 | 35.6 |
Total operating profit from discontinued operations amounted to 68.3 million in the first six months of
2024, compared to an operating profit of 39.0 million in the same period last year.
Net profit from discontinued operations related to
Jyseleca amounted to 71.0 million for the first six months of 2024, compared to a net profit amounting to 35.6 million for the first six months of 2023.
Cash, cash equivalents and current financial investments totaled 3,430.4 million as of 30 June 2024, as compared to
3,684.5 million as of 31 December 2023. Total net decrease in cash and cash equivalents and current financial investments amounted to 254.1 million during the first six months of 2024, compared to a net decrease of
192.5 million during the first six months of 2023. This net decrease was composed of (i) 250.0 million of operational cash burn including 78.6 million cash impact of business development activities, (ii)
36.9 million for the acquisition of financial assets held at fair value through other comprehensive income, (iii) 31.2 million of net cash in related to the sale of the
Jyseleca business to Alfasigma of which 40.0 million has been transferred to an escrow account, offset by (iv) 41.6 million of positive exchange rate differences,
positive changes in fair value of current financial investments and variation in accrued interest income.
The cash burn guidance for full year
2024, not including business development, is confirmed in the range of 280 million to 320 million. Our cash burn guidance for 2024 including business development to date is 370 million to 410 million.
Advancing current pipeline and strengthening capabilities
We continue to strengthen our capabilities in cell therapy and small molecules internally and through strategic business development and are advancing multiple
clinical and preclinical candidates across various indications and modalities. Before year-end, we anticipate:
CONFERENCE CALL AND WEBCAST PRESENTATION
We will host a conference call and webcast presentation on 2 August 2024, at 14:00 CET / 8:00 am ET. To participate in the conference call, please
register in advance using this link. Dial-in numbers will be provided upon registration. The conference call can be accessed 10 minutes prior to the start of the call by using the conference access information
provided in the email received after registration, or by selecting the call me feature.
The live webcast is available on glpg.com or
via the following link. The archived webcast will be available for replay shortly after the close of the call on the investor section of the website.
| FINANCIAL CALENDAR 2024 | ||||
| 30 October 2024 | Third quarter 2024 results | (webcast: 31 October 2024) | ||
| 12 February 2025 | Full year 2024 results | (webcast: 13 February 2025) |
biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and
collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. With capabilities from lab to patient,
including a decentralized cell therapy manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. For additional information, please
For further information, please contact:
| Media inquiries: | Investor inquiries: | |
| Marieke Vermeersch | Sofie Van Gijsel | |
| +32 479 490 603 | +1 781 296 1143 | |
| media@glpg.com | ir@glpg.com | |
| Jennifer Wilson | Sandra Cauwenberghs | |
| + 44 7444 896759 | +32 495 58 46 63 | |
| media@glpg.com | ir@glpg.com |
Forward-looking statements
This press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as believe, anticipate, plan, upcoming, future, estimate, may, will, could,
would, potential, forward, goal, next, continue, should, encouraging, aim, progress, remain, advance,
ambition, outlook, further, as well as similar expressions. These statements include, but are not limited to, the guidance from management regarding our financial results (including guidance regarding
the expected operational use of cash for the fiscal year 2024), statements regarding our regulatory outlook, statements regarding the amount and timing of potential future milestones, including potential milestone payments, statements regarding our
R&D plans, strategy and outlook, including progress on our oncology or immunology portfolio, our CAR-T-portfolio and our SIKi-portfolio, and potential
changes of such plans, statements regarding our pipeline and complementary technology platforms facilitating future growth, statements regarding our regulatory and R&D outlook, statements regarding the expected timing, design and
readouts of ongoing and planned clinical trials, including but not limited to (i) GLPG3667 in SLE and DM, (ii) GLPG5101 in R/R NHL, (iii) GLPG5201 in R/R CLL, and (iv) GLPG5301 in R/R MM, statements regarding our
commercialization efforts for our product candidates and any of our future approved products, if any, statements about potential future commercial manufacturing of T-cell therapies, statements
regarding our expectations on commercial sales of any of our product candidates (if approved), statements related to the anticipated timing for submissions to regulatory agencies, including any INDs or CTAs, statements relating to the
development of our distributed manufacturing capabilities on a global basis, and statements related to our portfolio goals and business plans. Galapagos cautions the reader that forward-looking statements are based on our management s
current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial
conditions and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or
implied by such forward-looking statements. In addition, even if Galapagos results, performance, financial condition
and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future
periods. Such risks include, but are not limited to, the risk that our expectations and management s guidance regarding our 2024 operating expenses, cash burn and other financial estimates may be incorrect (including because one
or more of our assumptions underlying our revenue and expense expectations may not be realized), the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all, the
inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the risk that data
from our ongoing and planned clinical research programs in DM, SLE, relapsed/refractory NHL, R/R CLL, R/R MM and other immunologic and oncologic indications or any other indications or diseases, may not support registration
or further development of our product candidates due to safety or efficacy concerns or other reasons), risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated
benefits of the acquisitions of CellPoint and AboundBio, the risk that the preliminary and topline data from our studies, including the ATALANTA-1, EUPLAGIA-1 and PAPILIO-1-studies, may not be reflective of the final data, risks related to our reliance on collaborations with third parties (including, but not limited
to, our collaboration partners Gilead, Lonza, Adaptimmune, BridGene Biosciences and Blood Centers of America), the risk that the transfer of the Jyseleca business will not have the
currently expected results for our business and results of operations, the risk that our plans with respect to our CAR-T program may not be achieved on the currently anticipated timeline or at all, the
risk that our estimates of the commercial potential of our product candidates (if approved) or expectations regarding the costs and revenues associated with any commercialization rights may be inaccurate, the risk that we will not be
able to continue to execute on our currently contemplated business plan and/or will revise our business plan, the risks related to our strategic transformation, including the risk that we may not achieve the anticipated
benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and
Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks
and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in
which we operate are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of
this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless
specifically required by law or regulation.
i The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to
the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
This alternative liquidity measure is in our view an important metric
for a biotech company in the development stage. The operational cash burn for the first six months of 2024 amounted to 250.0 million and can be reconciled to our cash flow statement by considering the decrease in cash and cash equivalents